| 1.67 0.02 (1.21%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.03 | 1-year : | 2.37 |
| Resists | First : | 1.74 | Second : | 2.03 |
| Pivot price | 1.46 |
|||
| Supports | First : | 1.37 | Second : | 1.14 |
| MAs | MA(5) : | 1.66 |
MA(20) : | 1.42 |
| MA(100) : | 1.22 |
MA(250) : | 1.51  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 86.7 | D(3) : | 87.5 |
| RSI | RSI(14): 64.8 |
|||
| 52-week | High : | 3.59 | Low : | 0.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DRRX ] has closed below upper band by 18.1%. Bollinger Bands are 32.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.69 - 1.7 | 1.7 - 1.71 |
| Low: | 1.62 - 1.63 | 1.63 - 1.64 |
| Close: | 1.66 - 1.67 | 1.67 - 1.68 |
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Tue, 21 May 2024
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - PR Newswire
Tue, 14 May 2024
DURECT Corporation (NASDAQ:DRRX) Q1 2024 Earnings Call Transcript - Insider Monkey
Tue, 14 May 2024
Pro Research: Wall Street dives into CRISPR Therapeutics' gene editing future By Investing.com - Investing.com
Mon, 13 May 2024
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update - PR Newswire
Wed, 27 Mar 2024
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 31 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 5.9 (%) |
| Held by Institutions | 22.9 (%) |
| Shares Short | 1,180 (K) |
| Shares Short P.Month | 1,050 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.27 |
| Profit Margin | -279.8 % |
| Operating Margin | -313 % |
| Return on Assets (ttm) | -41.8 % |
| Return on Equity (ttm) | -197 % |
| Qtrly Rev. Growth | -11.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.26 |
| EBITDA (p.s.) | -1.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -1.8 |
| PEG Ratio | -0.2 |
| Price to Book value | 6.18 |
| Price to Sales | 6.23 |
| Price to Cash Flow | -1.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|